Genzyme Predicts $5 Bil. In Annual Revenues By 2010 From Current Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is anticipating its forthcoming Pompe disease therapy Myozyme to contribute to growth starting in 2006.
You may also be interested in...
Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Wirth talks about Genzyme’s contentious acquisition of AnorMED and current shareholder objections to the company’s bid to acquire clofarabine partner Bioenvision.